Pharmaceutical

Sutro strengthens its immuno-oncology pipeline with two new ADCs

In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.

Aug 12, 2023 - 20:00
Sutro strengthens its immuno-oncology pipeline with two new ADCs
In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.
Read the original article

Tags:

Previous Article

Clinigen clears out cancer therapies in line with latest growth strategy

Next Article

Signal: Wave of layoffs in medical start-ups exposes underlying vulnerability

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Genprex’s Reqorsa gene therapy secures another FDA fast-track designation

Genprex’s Reqorsa gene therapy secures another FDA fast...

Jun 29, 2023

Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry

Leading innovators in anti-influenza antibody compositi...

May 8, 2023

STAT+: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs

STAT+: FDA’s Califf talks cell and gene therapies, abor...

Apr 19, 2023